Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Top Page
Xeris Pharmaceuticals
(NASDAQ:XERS)
Rating:54Neutral
Price Target:
$4.50
▼(-4.86%Downside)
Positive Factors
Financial Performance
Xeris delivered strong revenues, representing around 48% year-over-year growth, marking another consecutive quarter of over 20% year-over-year growth.
Product Growth
Record growth of Recorlev with revenue growing approximately 141% year-over-year, driven by a 124% increase in average patients on therapy.
Strategic Outlook
Xeris' record 4Q24 performance marks a transformative inflection point with accelerating commercial momentum and first-time positive adjusted EBITDA, which is a strong positive setup going into 2025.
Negative Factors
Investor Concerns
Some investors might still want more granular details on the roadmap for Recorlev becoming a blockbuster product, which could take some time.
Transparency
The company has a tighter revenue guidance, which suggests confidence in achieving financial targets.
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$746.32M
Dividend YieldN/A
Average Volume (3M)2.10M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth29.88%
EPS Growth35.11%
CountryUS
Employees394
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding160,155,000
10 Day Avg. Volume2,314,002
30 Day Avg. Volume2,100,256
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)-19.88
Price to Sales (P/S)0.00
P/FCF Ratio-26.75
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit5.24
Enterprise Value/Ebitda-14.99
Forecast
1Y Price Target
$6.00Price Target Upside26.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Xeris Pharmaceuticals Business Overview & Revenue Model
Company DescriptionXeris Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative injectable and infusible drug formulations. The company's technology platform, XeriSol, enables the subcutaneous and intramuscular delivery of highly concentrated, ready-to-use liquid formulations of therapies that traditionally required reconstitution or intravenous administration. Xeris Pharmaceuticals' flagship product is Gvoke, a glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
How the Company Makes MoneyXeris Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, including Gvoke. The company's revenue model is based on the commercialization and distribution of its proprietary drug formulations. Xeris leverages partnerships with healthcare providers, distributors, and pharmacies to expand its market reach and increase product adoption. Additionally, Xeris may engage in licensing agreements or collaborations with other pharmaceutical companies to further monetize its technology platform and product pipeline. The company's earnings are influenced by factors such as market demand for its products, pricing strategies, and the effectiveness of its sales and marketing efforts.
Xeris Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 5.58%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment with significant revenue growth, a successful product portfolio, and strategic FDA approval. While there is an increase in SG&A expenses, the overall performance remains robust, supported by strong financial metrics and promising pipeline developments.Q1-2025 Updates
Positive Updates
Record-Breaking Revenue Growth
Total revenue grew 48% year-over-year to $60.1 million, marking the fourteenth consecutive quarter of over 20% product revenue growth.
Strong Performance of Recorlev
Recorlev net revenue was $25.5 million, up 141% compared to last year, with a 24% increase in the average number of patients.
FDA Approval for Gvoke VialDx
Gvoke VialDx received FDA approval, expanding its use as a diagnostic aid during radiologic examination, in partnership with American Regent.
Positive Adjusted EBITDA
Adjusted EBITDA for the quarter was a positive $4.4 million, supporting the commitment to delivering positive adjusted EBITDA going forward.
Strong Gross Margin
Gross margin in the quarter was 85%, showing a sequential improvement of 200 basis points due to a favorable product mix.
Pipeline Progress with XP-8121
Development of XP-8121 continues to address unmet needs in the hypothyroidism market, with more updates expected at the analyst and investor day.
Negative Updates
Increased SG&A Expenses
Selling, general, and administrative expenses were $44 million, a 15% increase compared to the prior year, influenced by commercial expansion and personnel costs.
Company Guidance
In the call, Xeris Biopharma Holdings, Inc. provided guidance updates and highlighted strong financial performance metrics for the first quarter of 2025. Total revenue grew by 48% year-over-year, reaching $60.1 million, driven by a 41% increase in Recorlev revenue, which exceeded $25 million. The company raised the lower end of its full-year revenue guidance from $255 million to $260 million, indicating an implied full-year total revenue growth of nearly 32% at the midpoint. The gross margin for the quarter was 85%, and the company achieved a positive adjusted EBITDA of $4.4 million. Xeris also noted strategic advancements, such as the FDA approval of Gvoke VialDx and a partnership with American Regent for its commercialization. The company aims to maintain financial discipline, with SG&A and R&D expenses projected to grow in the mid to high single digits, and it plans to remain adjusted EBITDA positive moving forward.Xeris Pharmaceuticals Financial Statement Overview
Summary
Xeris Pharmaceuticals shows significant revenue growth, but faces challenges with profitability and leverage. Positive strides in operational efficiency are noted, yet negative equity and cash flow issues pose risks.Income Statement
Xeris Pharmaceuticals has shown significant revenue growth, with Total Revenue increasing from $49.59M in 2020 to $222.55M in TTM (Trailing-Twelve-Months). Gross Profit Margin remains strong, but the company is facing challenges with profitability, as evidenced by negative Net Profit Margin and EBIT Margin. The company is improving its EBITDA Margin, indicating better operational efficiency.65
Positive
Balance Sheet
The company's balance sheet reveals high leverage with a negative Stockholders' Equity and a substantial Debt-to-Equity Ratio, indicating financial risk. Despite growing assets, the negative equity and increasing total liabilities highlight potential solvency concerns. The Equity Ratio reflects this weak equity position.40
Negative
Cash Flow
Xeris Pharmaceuticals has improved its Free Cash Flow year-over-year, but it remains negative, indicating cash constraints. The Operating Cash Flow to Net Income Ratio suggests operational cash flow struggles. The company must focus on enhancing cash flow generation to support growth and reduce reliance on external financing.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 222.55M | 203.07M | 163.91M | 110.25M | 49.59M | 49.59M |
| Gross Profit | 180.25M | 166.24M | 135.27M | 87.61M | 36.27M | 36.27M |
| EBITDA | -8.66M | -11.30M | -23.73M | -69.31M | -113.67M | -80.08M |
| Net Income | -45.08M | -54.84M | -62.26M | -94.66M | -122.72M | -122.72M |
Balance Sheet | ||||||
| Total Assets | 108.99M | 323.06M | 322.60M | 344.52M | 344.52M | 304.36M |
| Cash, Cash Equivalents and Short-Term Investments | 75.55M | 71.62M | 72.45M | 121.97M | 121.97M | 102.43M |
| Total Debt | 58.30M | 271.45M | 229.19M | 198.06M | 198.06M | 88.07M |
| Total Liabilities | 94.55M | 352.68M | 329.38M | 299.33M | 299.33M | 209.13M |
| Stockholders Equity | 14.44M | -29.61M | -6.78M | 45.19M | 45.19M | 95.23M |
Cash Flow | ||||||
| Free Cash Flow | -27.43M | -37.85M | -49.29M | -103.42M | -103.42M | -96.62M |
| Operating Cash Flow | -26.71M | -36.98M | -47.02M | -102.89M | -102.89M | -95.53M |
| Investing Cash Flow | 24.52M | 4.88M | -6.00M | 34.46M | 34.46M | 97.96M |
| Financing Cash Flow | -2.16M | 36.17M | -1.61M | 127.47M | 127.47M | 27.25M |
Xeris Pharmaceuticals Technical Analysis
Positive
4.73
Price Trends
4.64
Positive
4.53
Positive
3.88
Positive
Market Momentum
0.01
Negative
54.12
Neutral
57.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 4.73 is above the 20-day moving average (MA) of 4.56, above the 50-day MA of 4.64, and above the 200-day MA of 3.88, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.12 is Neutral, neither overbought nor oversold. The STOCH value of 57.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xeris Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £5.95B | 9.21 | -57.69% | 4.67% | 15.15% | -8.16% | |
58 Neutral | $1.04B | ― | -15.59% | ― | -35.41% | -12.26% | |
56 Neutral | $892.72M | ― | -64.16% | ― | -30.25% | -5.92% | |
54 Neutral | $746.32M | ― | 222.83% | ― | 29.88% | 35.11% | |
49 Neutral | $871.84M | ― | -29.80% | ― | 85.05% | 15.96% | |
49 Neutral | $879.33M | ― | -63.56% | ― | 270.02% | 32.69% | |
46 Neutral | $574.35M | ― | -33.48% | ― | -25.88% | -29.16% |
* Healthcare Sector Average
Performance Comparison
XERS
Xeris Pharmaceuticals
4.73
2.62
124.17%
XNCR
Xencor
8.30
-9.93
-54.47%
ZYME
Zymeworks
12.89
4.01
45.16%
NRIX
Nurix Therapeutics
12.44
-7.03
-36.11%
PRAX
Praxis Precision Medicines
46.32
6.00
14.88%
ABCL
AbCellera Biologics
3.75
1.06
39.41%
Xeris Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting
Neutral
Jun 4, 2025
On June 4, 2025, Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Three individuals were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved the compensation of the Company’s Named Executive Officers on a non-binding advisory basis.
The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.
Business Operations and StrategyFinancial Disclosures
Xeris Pharmaceuticals Hosts Analyst and Investor Day
Positive
Jun 3, 2025
Xeris Pharmaceuticals announced its first Analyst and Investor Day scheduled for June 3, 2025, in New York City, where senior management will discuss the company’s growth strategy and financial outlook. The event aims to highlight the potential of products like Recorlev® and XP-8121, emphasizing their expected impact on revenue growth and the treatment landscape for conditions such as hypothyroidism, potentially affecting stakeholders by demonstrating the company’s commitment to long-term value creation.
The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.